Effects of HIV triple therapy on methadone levels

American Journal on Addictions

Volumn 11, Issue 4, 2002, Pages 308-314

  Akerele, Evaristo O ^a   Levin, Frances ^a   Nunes, Edward ^a   Brady, Ronald ^b   Kleber, Herbert ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Bridge Plaza Clinic ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; METHADONE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; WITHDRAWAL SYNDROME; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG INTERACTION; HEROIN DEPENDENCE; MIDDLE AGED;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; MALE; METHADONE; MIDDLE AGED;

EID: 0036755609     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1080/1055049029008810     Document Type: Article

References (21)

1. Richardson L. Infected addicts avoid AIDS drugs, fearing they affect methadone. New York Times. July 19, 1998;sect I:23.
2. Hamilton SP, Nunes EV, Janal M and Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict. 2000;9(1):63-69.
3. Payte JT, Zweben JE. Opiod Maintenance Therapies. In: Graham AW, Schultz TK, eds. Principles of Addiction Medicine, 2nd Edition. Chevy Chase, American Society of Addiction Medicine;1998:557-570.
4. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition. AIDS Clinical Trials Group 262. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(5):435-443.
5. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32(3):194-209.
6. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 1996;52(1):93-112.
7. Iribame C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos. 1998;26(3):257-60.
8. Guibert A, Furlan V, Martino J, Taburet A. In vitro effect of HIV protease inhibitors on methadone metabolism. In:37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997.
9. Hsu A, Granneman GR, Dennis S, Chiu YL, Valdes J, Sun E. Ritonavir does not increase methadone exposure in healthy volunteers. In:5th Annual Conference on Retroviruses. Abbott Park, II: Abbott Laboratories; 1998.
10. Geletko SM, Erickson MD, Decreased methadone effect after ritonavir initiation. Pharmacotherapy. 2000;20(1):93,94.
11. Hsu A, Granneman GR, Bertz RJ. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics. 1998;35(4):275-279.
12. Kalow W. ed., Pharmacogenetics of Drug Metabolism. New York:Pergamon; 1992.
13. Lin KM, Pland RE, Nakasaki G. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC:American Psychiatric Press; 1993.
14. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. In: O'Brien CP, Jaffe JH, eds. Addictive States. New York, NY:Raven Press; 1992:205-230.
15. Grudzinkas CV, Woosley RL. The documented role of pharmacogenetics in the identification and administration of new medications for treating drug abuse. NIDA Research Monograph. 1996;162:60-63.
16. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs. high-dose methadone in the treatment of opioid dependence: A randomized trial. JAMA. 1999;281(11):1000-1005.
17. Lin KM, Poland RE, Lau JK. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol. 1988;8:195-201.
18. Chang SS, Pandey GN. Racial Differences in Plasma and RBC Lithium Levels (Paper 27). In:A merican Psychiatric Association. Washington, DC; 1984:239-249.
19. Hu WH, Lee CF, Yang YY. Imipramine plasma levels and clinical response. Bulletin of Chinese Society of Neyrology and Psychiatry. 1983;9:40-49.
20. Schenker S. Medical consequences of alcohol abuse: Is gender a factor? Alcohol Clin Exp Res. 1997;21(1):179-181.
21. Blume SB. ed. Women and Addictive Disorders: Principles of Addiction Medicine. Chevy Chase Md.: American Society of Addiction Medicine; 1998:15.1.1-15.1.30.